[A21-47] Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 02.08.2021
Project no.:
A21-47
Commission:
Commission awarded on 03.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Adults with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen, without resistance to, and no virological failure with non-nucleoside reverse transcriptase inhibitors (NNRTIs) or integrase inhibitors (INIs)
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.